NCT00085579撤回2 期
A Phase II Study of Maintenance Biotherapy With Interleukin-2 and Granulocyte-Macrophage Colony Stimulating Factor in Patients With Metastatic Melanoma With a Partial Response or Stable Disease After Systemic Therapy
适应症
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 试验地点
- 1
研究概览
简要总结
RATIONALE: Interleukin-2 and sargramostim may stimulate a person's white blood cells to kill melanoma cells.
PURPOSE: This phase II trial is studying how well giving interleukin-2 together with sargramostim works in treating patients with stage III or stage IV melanoma that was previously treated with chemotherapy.
详细描述
OBJECTIVES:
Primary
- Determine the frequency of complete response in patients with stage III or IV melanoma who have achieved either a partial response or stable disease after prior systemic chemotherapy and are treated with maintenance biotherapy comprising interleukin-2 and sargramostim (GM-CSF).
Secondary
- Determine the time to progression in patients treated with this regimen.
- Determine the effects of this regimen on lymphocyte subsets in these patients.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 16 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
Interleukin-2 in Treating Patients With Metastatic MelanomaMelanoma (Skin)NCT00002845Blumenthal Cancer Center at Carolinas Medical Center20
终止
1 期
Biological Therapies Following Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Advanced Breast CancerBreast CancerLymphomaNCT00005993Masonic Cancer Center, University of Minnesota
Unknown
3 期
Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the LiverMelanoma (Skin)Metastatic CancerNCT00039234Maxim Pharmaceuticals
终止
2 期
Interleukin-2 in Treating Patients With Mycosis Fungoides or Sezary SyndromeLymphomaNCT00005788Northwestern University
已完成
2 期
Interleukin-2 and Bryostatin 1 in Treating Patients With Advanced Kidney CancerRecurrent Renal Cell CancerStage III Renal Cell CancerStage IV Renal Cell CancerNCT00032188National Cancer Institute (NCI)65